Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06069791 · ClinicalTrials.gov registry record · Phase 1

Greater Occipital Nerve Blockade in Veterans With Post-concussion Headache: Sub-study 1

A Phase 1 study of Post-Traumatic Headache, sponsored by Yale University.

Recruiting
Registry status
Phase 1
Development phase
12
Enrollment target
1
Study location

NCT06069791: Recruiting Phase 1 study of Post-Traumatic Headache, sponsored by Yale University.

NCT06069791 is a Phase 1 study of Post-Traumatic Headache that is actively recruiting participants, run by Yale University. The registered enrollment target is 12 participants, below the 173-participant average among 11 other Post-Traumatic Headache trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06069791, a Phase 1 study of Post-Traumatic Headache, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
Phase 1
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The acute and subacute sensations that occur on the scalp with injection of different concentrations of bupivacaine for grater occipital nerve blockade will be compared. Each Veteran participant will be randomized to receive three different concentrations, which will be injected one week apart each.

Primary Outcome

The quality of the sensation on the scalp at the time of injection (e.g., burning, shooting, aching)

Conditions Studied

Interventions

  • DRUG Bupivacaine Injection

Study Locations (1)

Connecticut

  • VA Connecticut Healthcare System - West Haven

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2024-01-26
Est. Completion 2026-12-31
Phase Phase 1
Yale University

1,492 total trials

What NCT06069791 shows while recruiting

NCT06069791 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 173-participant average among 11 other Post-Traumatic Headache trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Post-Traumatic Headache appearing as the primary indexed condition, and to 1 intervention - of which Bupivacaine Injection is the first listed.

NCT06069791 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT06069791 about?

NCT06069791 is a clinical study titled "Greater Occipital Nerve Blockade in Veterans With Post-concussion Headache: Sub-study 1". The acute and subacute sensations that occur on the scalp with injection of different concentrations of bupivacaine for grater occipital nerve blockade will be compared. Each Veteran participant will be randomized to receive three different concentrations, which will be injected one week apart each.

What is the current status of trial NCT06069791?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-01-26. Estimated completion is 2026-12-31.

What conditions does trial NCT06069791 study?

This clinical trial studies the following conditions: Post-Traumatic Headache.

What interventions are being tested in trial NCT06069791?

The interventions under investigation include: Bupivacaine Injection (DRUG).

Who is sponsoring clinical trial NCT06069791?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06069791 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Post-Traumatic Headache

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06069791's enrollment target sits among peer trials

12 11th of 11 higher than 1 of 11 other Post-Traumatic Headache trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Post-Traumatic Headache trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06069791, the US trial registry maintained by the National Library of Medicine. NCT06069791 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.